Oramed Pharmaceuticals (ORMP) Non-Current Deffered Revenue (2016 - 2025)
Oramed Pharmaceuticals' (ORMP) quarterly Non-Current Deffered Revenue came in at $2.0 million in Q4 2025, down 50.0% YoY from $4.0 million in Q4 2024, and little changed on a QoQ basis from $2.0 million in Q3 2025.
Oramed Pharmaceuticals (ORMP) Non-Current Deffered Revenue (2016 - 2025) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 10 years of Non-Current Deffered Revenue data on file, last reported at $2.0 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 50.0% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 50.0% YoY) and the FY2025 annual result came in at $2.0 million, down 50.0% from the prior year.
- Non-Current Deffered Revenue held at $2.0 million in Q4 2025, from $2.0 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $5.6 million in Q1 2021 to a low of $2.0 million in Q2 2022.
- A 5-year average of $3.6 million and a median of $4.0 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue surged 100.0% — and 2025, when it sank 50.0%.
- Tracing ORMP's Non-Current Deffered Revenue over 5 years: stood at $3.6 million in 2021, then advanced by 12.04% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then changed by 0.0% to $4.0 million in 2024, then slumped by 50.0% to $2.0 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 4.00 Mn |
| Dec 31, 2023 | 4.00 Mn |
| Sep 30, 2023 | 4.00 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 4.00 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 2.67 Mn |
| Nov 30, 2021 | 3.57 Mn |
| Aug 31, 2021 | 4.24 Mn |
| May 31, 2021 | 4.93 Mn |
| Feb 28, 2021 | 5.61 Mn |